Medicina clinica · 2023
Efficacy and safety of convalescent plasma administration in patients with COVID-19 infection.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Escobedo-Sánchez Priscila Edith, de la Cruz-Hernández Ibis, Ramos-García Meztli, Sánchez-Yedra Iván, García-Vázquez Carlos, Guzmán-Priego Crystell Guadalupe, García-Vidrios María Victoria, Olvera-Hernández Viridiana, Mendoza-García Yolanda, Ble-Castillo Jorge Luis
Аннотация
INTRODUCTION: During the COVID-19 pandemic, several strategies were suggested for the management of the disease, including pharmacological and non-pharmacological treatments such as convalescent plasma (CP). The use of CP was suggested due to the beneficial results shown in treating other viral diseases.
OBJECTIVE: To determine the efficacy and safety of CP obtained from whole blood in patients with COVID-19.
METHODS: Pilot clinical trial in patients with COVID-19 from a general hospital. The subjects were separated into three groups that received the transfusion of 400ml of CP (n=23) or 400ml of standard plasma (SP) (n=19) and a non-transfused group (NT) (n=37). Patients also received the standard available medical treatment for COVID-19. Subjects were followed up daily from admission to day 21.
RESULTS: The CP did not improve the survival curve in moderate and severe variants of COVID-19, nor did it reduce the degree of severity of the disease evaluated with the COVID-19 WHO and SOFA clinical progression scale. No patient had a severe post-transfusion reaction to CP.
CONCLUSIONS: Treatment with CP does not reduce the mortality of patients even when its administration has a high degree of safety.
OBJECTIVE: To determine the efficacy and safety of CP obtained from whole blood in patients with COVID-19.
METHODS: Pilot clinical trial in patients with COVID-19 from a general hospital. The subjects were separated into three groups that received the transfusion of 400ml of CP (n=23) or 400ml of standard plasma (SP) (n=19) and a non-transfused group (NT) (n=37). Patients also received the standard available medical treatment for COVID-19. Subjects were followed up daily from admission to day 21.
RESULTS: The CP did not improve the survival curve in moderate and severe variants of COVID-19, nor did it reduce the degree of severity of the disease evaluated with the COVID-19 WHO and SOFA clinical progression scale. No patient had a severe post-transfusion reaction to CP.
CONCLUSIONS: Treatment with CP does not reduce the mortality of patients even when its administration has a high degree of safety.